Quick Overview: Dr. Edith Perez on the Etirinotecan Pegol for HER2-Negative Breast Cancer Dr. Edith Perez on the development of targeted therapies Cancer risk is shaped by more than genetics, and this video reveals everyday factors that may influence your cells and the simple ...

Dr Edith Perez On Immune - Detailed Overview & Context

Dr. Edith Perez on the Etirinotecan Pegol for HER2-Negative Breast Cancer Dr. Edith Perez on the development of targeted therapies Cancer risk is shaped by more than genetics, and this video reveals everyday factors that may influence your cells and the simple ... I'm a VPN head of by oncology us medical affairs for genentech and I'm also a

Photo Gallery

Dr. Edith Perez on Immune Checkpoint Inhibition in Triple-Negative Breast Cancer
Dr. Perez on Immune Checkpoint Inhibition in Breast Cancer
Dr. Edith Perez on the Antibody-Drug Conjugate T-DM1
Dr. Edith Perez Discusses BOLERO-1 Trial Results for HER2-Positive Breast Cancer
Dr. Edith Perez Discusses the Adjuvant Treatment of Breast Cancer
Dr. Edith Perez on Adjuvant Treatments
Meet Dr. Edith Perez | Minority Health Month | Stand Up To Cancer
Dr. Edith Perez Discusses Her Ongoing Research
Dr. Edith Perez Discusses Adjuvant Chemotherapy Patient Selection
Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER+ Breast Cancer Patients
Translational Genomics: The Future is Now | Edith Perez, MD
Dr. Edith Perez on the Etirinotecan Pegol for HER2-Negative Breast Cancer
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored